Cystitis– Pipeline Review, 2019

Cystitis is an inflammation of the bladder which is caused by a bacterial infection known as urinary tract infection (UTI). It can be painful and can lead to serious health issues is the infection spreads to the kidney. A burning sensation while urinating, passing cloudy or smelly urine, having a low-grade fever, feeling of pressure at the lower abdomen and strong urge to urinate are some of the common symptoms associated with cystitis.

Apart from bacteria-induced infection, non-infectious factors can also cause inflammation of the bladder. For instance, cystitis can arise due to the use of various medications especially chemotherapy drugs such as ifosfamide and cyclophosphamide which causes inflammation of the bladder when the drugs exit the body. It can also occur due to long term use of bladder catheters, having various chronic disorders such as diabetes and kidney stones.

According to the report published in National Center for Biotechnology (NCBI) around 40%, women experience urinary tract infection (UTI) which leads to 100,000 hospital admissions, 8 million clinics or emergency visit resulting $1.6 billion in healthcare cost annually. Antibiotics such as are nitrofurantoin, trimethoprim-sulfamethoxazole, amoxicillin, cephalosporins, ciprofloxacin, and levofloxacin are used for the treatment of bacterial cystitis. Additionally, histamine blockers, pentosan, and immunosuppressants, such as cyclosporine and mycophenolate can be used to treat the pain associated with Interstitial cystitis.

Many research institutes and pharmaceutical companies have been focusing on studying and developing new treatment options for cystitis. For instance; AQX-1125, which is being studied by – Aquinox Pharmaceuticals (Canada) Inc., is currently in phase-2 clinical trials for study is to evaluate the effect of 6 weeks of treatment with once daily administration of AQX-1125 compared to placebo on average daily pain in subjects with interstitial cystitis/bladder pain syndrome (IC/BPS), during and after treatment, using a standardized 11-point numerical rating scale (NRS) pain score recorded by electronic diary.

At present around 89% of the pipeline candidates for Cystitis are in the phase-2 and phase-4 stage. More than half of the studies are sponsored by research institutes.

Report Description

The report on ‘Cystitis– Pipeline Review, 2019’ provides a comprehensive overview of the drugs that are in the R&D pipeline by indication or molecule for Cystitis. The report provides a thorough analysis of the distribution of the pipeline products by clinical trial stage, indication, company, therapy area and details such as clinical trial stage, sponsor, description on every product in the pipeline. Products in the preclinical and clinical stage along with dormant & discontinued pipeline candidates are included in the report. The report also covers additional insights such as epidemiology overview and current market scenario for Acromegaly.

The report on ‘Cystitis– Pipeline Review, 2019’, which is built by following a robust research methodology involving primary interviews and desk research, provides a complete overview of the R&D activity and pipeline products to assist companies in developing growth strategies and identifying emerging players.

Report Scope

• Thorough assessment of the pipeline products by areas such as development stage; route of administration; drug class; indication; sponsor; molecule type and drug target


• Comprehensive profiles of the pipeline products with details such as company overview; product description; R&D status; development activities; mechanism of action; molecule type; development stage; indications; funding and route of administration


• Overview of dormant and discontinued pipeline products


• Key insights in relation to the epidemiology of conditions being treated by the pipeline products and overview of the addressable or current market for the pipeline products


• Overview of the latest developments; news articles, press releases and relevant conferences

Report Methodology

• All pipeline reports are built through the analysis of data primarily collected through credible desk research sources. Secondary research is supplemented by interviews conducted with key opinion leaders.


• Desk research sources includes global and regional clinical trials databases; annual reports, websites, press releases & investor presentations of companies; white papers; news articles; reports published by industry associations; articles/reports published on databases such as NCBI, ResearchGate; internal databases

Reasons to Buy this Report

• Develop effective growth strategies based on comprehensive overview of the R&D activity and pipeline products forCystitis


• Identify emerging players or competition in the market based on pipeline products and develop strategies to counter the emergence of these players


• Identify the focus of leading players in relation to R&D for Cystitis


• Identify potential companies from a partnership or acquisition point of view based on current synergy in R&D activities or strategies to diversify R&D focus to drive growth in business


• Analyse the reasons behind dormant and discontinued products to make changes in the R&D focus if necessary